Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer

JAMA Oncol. 2020 Dec 1;6(12):1971-1972. doi: 10.1001/jamaoncol.2020.4749.

Authors

Robert S Copeland-Halperin¹, Mohammed Al-Sadawi², Sujata Patil^{3

4}, Jennifer E Liu^{1

4}, Richard M Steingart^{1

4}, Chau T Dang^{1

4}, Anthony F Yu^{1

4}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² SUNY Downstate Medical Center, Brooklyn, New York.
³ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer, New York, New York.
⁴ Weill Cornell Medical College, New York, New York.

Abstract

This cohort study evaluates the association of early trastuzumab interruption with clinical outcomes in patients with ERBB2-positive breast cancer.

MeSH terms

Antibodies, Monoclonal, Humanized
Breast Neoplasms* / drug therapy
Female
Humans
Receptor, ErbB-2
Trastuzumab / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab

Grants and funding